CureVac N.V. (CVAC)
| Market Cap | 834.42M |
| Revenue (ttm) | 64.13M |
| Net Income (ttm) | -297.07M |
| Shares Out | 224.31M |
| EPS (ttm) | -1.32 |
| PE Ratio | n/a |
| Forward PE | 9.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 333,142 |
| Open | 3.690 |
| Previous Close | 3.640 |
| Day's Range | 3.600 - 3.740 |
| 52-Week Range | 2.215 - 10.140 |
| Beta | 2.64 |
| Analysts | Hold |
| Price Target | 10.00 (+168.82%) |
| Earnings Date | Aug 15, 2024 |
About CVAC
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for tre... [Read more]
Financial Performance
In 2023, CureVac's revenue was 53.76 million, a decrease of -20.26% compared to the previous year's 67.42 million. Losses were -260.17 million, 4.47% more than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CVAC stock is "Hold." The 12-month stock price forecast is $10.0, which is an increase of 168.82% from the latest price.
News
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) sc...
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more...
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
The deal represents a vote of confidence in the future of the mRNA-based vaccine market.
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
U.S.-listed shares of CureVac NV surged on Wednesday after GSK PLC announced an offer worth up to $1.56 billion (€1.44 billion) for the rights to the German biopharmaceutical's COVID-19 and flu vaccin...
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to a...
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-va...
GSK buys full rights to make COVID, influenza vaccines from CureVac
GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euro...
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based o...
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA)...
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and stra...
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will...
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise Collaboration aims to develop novel, off-the-sh...
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Potentially differentiated, multivalent candidate encodes antigens matched to all four WHO-recommended flu strains For influenza A strains, geometric mean titers numerically exceeded those elicited by...
CureVac stock gains as COVID vaccine candidates show promise
CureVac N.V. shares CVAC, +1.20% gained 3% premarket on Friday as the company released new data from a trial of its mRNA COVID-19 vaccine candidates, which it is developing in collaboration with GSK P...
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile Monovalent mRNA vaccine candidate, ...
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE Decision does not affect ongoing litigation in Germany regarding seven other ...
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine can...
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
COVID-19 Phase 2 clinical trial fully enrolled Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine First participant dosed in seasonal flu Phase 2 part of...
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech Ruling on infringement to be provided latest once the validity...
CureVac signals progress on mRNA flu vaccine
CureVac NV CVAC, -3.85% said Tuesday that it has selected an mRNA flu vaccine candidate for continued clinical development, based on positive results from an early-stage study conducted in collaborati...
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate Best-performing candidate providing broad...
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Initiated Ph...
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates Vaccine candidates developed in collaboration with GSK within COVID-19 vaccine deve...
Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology
NEW YORK--(BUSINESS WIRE)--Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically de...